Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues

Impact of Atrial Fibrillation on the Risk of Death

1998 • 4,449 citations

Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study

1994 • 2,959 citations

Epidemiologic Features of Chronic Atrial Fibrillation

1982 • 2,347 citations

Independent Risk Factors for Atrial Fibrillation in a Population-Based Cohort

1994 • 2,288 citations

Cardiac Electrophysiology: From Cell to Bedside

1991 • 2,234 citations

Prevalence, Age Distribution, and Gender of Patients With Atrial Fibrillation

1995 • 2,148 citations

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary

2006 • 1,182 citations

Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction

1999 • 1,013 citations

Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs

1993 • 843 citations

Low Penetrance in the Long-QT Syndrome

1999 • 817 citations

Female Gender as a Risk Factor for Torsades de Pointes Associated With Cardiovascular Drugs

1993 • 702 citations

Acc/aha/esc guidelines for the management of patients with atrialfibrillation: executive summary a report of the american college ofcardiology/american heart association task force on practice guideli

2001 • 608 citations

Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients.

1991 • 572 citations

ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology

2001 • 571 citations

Age- and Sex-Related Differences in Clinical Manifestations in Patients With Congenital Long-QT Syndrome

1998 • 481 citations

Sex Difference in Risk of Torsade de Pointes With d,l- Sotalol

1996 • 447 citations

Evidence for a Cardiac Ion Channel Mutation Underlying Drug‐Induced QT Prolongation and Life‐Threatening Arrhythmias

2000 • 313 citations

Risk for systemic embolization of atrial fibrillation without mitral stenosis

1990 • 206 citations

Age-Gender Influence on the Rate-Corrected QT Interval and the QT-Heart Rate Relation in Families With Genotypically Characterized Long QT Syndrome

1997 • 193 citations

Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function

1993 • 179 citations

Proarrhythmia with Class III Antiarrhythmic Drugs: Definition, Electrophysiologic Mechanisms, Incidence, Predisposing Factors, and Clinical Implications

1995 • 153 citations

Mortality in the Survival With ORal D-Sotalol (SWORD) Trial: Why Did Patients Die? 11This work was supported by a grant from Bristol-Myers Squibb, Princeton, New Jersey.

1998 • 146 citations

Aggravation of arrhythmia by antiarrhythmic drugs—Incidence and predictors

1987 • 135 citations

Gender differences in arrhythmias

2002 • 113 citations

[Torsades de pointes].

1993 • 108 citations

Ionic Remodeling of Cardiac Purkinje Cells by Congestive Heart Failure

2001 • 102 citations

JTc prolongation with d,l-sotalol in women versus men

1999 • 96 citations

Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required?

1998 • 88 citations

Age and Gender Influences on Rate and Duration of Paroxysmal Atrial Fibrillation

1998 • 74 citations

Azimilide Dihydrochloride, a Novel Antiarrhythmic Agent

1998 • 71 citations

Hypokalemia-Induced Long QT Syndrome with an Underlying Novel Missense Mutation in S4-S5 Linker of KCNQ1

2000 • 71 citations

New advances in class III antiarrhythmic drug therapy

1999 • 46 citations

Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias11∗Disclosure: This study was not written with support from or discussion with any pharmaceutical manufacturer.

2000 • 44 citations

Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: Efficacy and dose-response

2002 • 37 citations

Issues in the use of generic antiarrhythmic drugs

2001 • 36 citations

New advances in class III antiarrhythmic drug therapy

2000 • 29 citations

Efficacy and Proarrhythmia with the Use of d,l-sotalol for Sustained Ventricular Tachyarrhythmias

1997 • 26 citations

Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter

1998 • 24 citations

Optimal Management with Class I and Class III Antiarrhythmic Drugs Should Be Done in the Outpatient Setting

1999 • 22 citations

Predictive Factors of Ventricular Fibrillation Triggered by Pause-Dependent Torsades de Pointes Associated with Acquired Long QT Interval:.

2000 • 21 citations

Inpatient versus outpatient antiarrhythmic drug initiation: safety and cost-effectiveness issues

2000 • 17 citations

Antiarrhythmic therapy in heart failure.

2002 • 12 citations